Top Stocks in the News LXRX, SYTA, DBVT, WIMI, MLGO, and PRTG

March 28, 2025

DENVER, Colo., Mar 28, 2025 (247marketnews.com)- Lexicon Pharmaceuticals (NASDAQ:LXRX) just inked a blockbuster deal with Novo Nordisk A/S, handing over the keys to LX9851, a first-in-class oral non-incretin obesity drug, in an exclusive worldwide license worth up to $1 billion. Announced today, the pact nets Lexicon $75 million upfront and near-term milestone cash, with the potential for a $1 billion in development, regulatory, and sales payouts—plus tiered royalties on every sale.

LX9851, Lexicon’s brainchild, is a potent oral inhibitor of Acyl-CoA Synthetase 5 (ACSL5)—a fat-regulating powerhouse that tweaks energy balance and fires up the ileal brake to curb appetite and slow digestion. Preclinical data from Obesity Week 2024 lit up the charts: paired with semaglutide, LX9851 slashed weight, appetite, and fat mass beyond semaglutide’s solo punch. Post-semaglutide, it tamed weight regain and eased liver fat—a double whammy for the $100 billion obesity market.

Siyata Mobile (NASDAQ:SYTA) is gearing up to release its Q4 and full-year 2024 financial report on March 31, 2025, but don’t expect the usual earnings call chatter. This time, Siyata’s playing a different game.

With the upcoming blockbuster Core Gaming merger, the combined companies’ leaders will present at the AI & Technology Virtual Investor Conference on April 3, Core’s CEO Aitan Zacharin will unpack the strategy fueling this seismic shift VirtualInvestorConferences.com at 10:30 AM ET.

Siyata’s not just a Push-to-Talk (PoC) handset maker anymore; its $185 million merger with Core Gaming is rewriting the playbook. Core, a Miami-based mobile gaming titan, boasts $80 million in 2024 revenue, 40 million monthly active users (MAUs), and 600 million downloads across 2,000+ games in 140 countries. ValueScope pegged Core’s November valuation at $185.9 million and Zacharin’s April 3 presentation promises to dive into its AI-powered growth, think apps that hook players and rake in cash, eyeing a $126 billion mobile gaming market.

DBV Technologies (NASDAQ:DBVT) just closed a blockbuster financing deal worth up to $306.9 million (€284.5 million) to turbocharge its Viaskin Peanut Patch. The haul includes $125.5 million (€116.3 million) upfront and up to $181.4 million (€168.2 million) more if warrants fully cash out, fueling the patch’s sprint through a Biologics License Application (BLA) to the FDA and a potential U.S. launch for kids aged 4-7, pending approval.

WiMi Hologram Cloud (NASDAQ:WIMI) just dropped a bombshell: it boosted its stake in MicroAlgo (NASDAQ:MLGO) to a hefty 67.65%. Plus, it’s locking in its shares for 10-years.

This move sees WiMi, a Beijing-based augmented reality (AR) innovator, tightening its grip on MicroAlgo, a tech outfit dabbling in algorithm optimization and quantum research. WiMi now holds 40,000 Class A common shares, 1.8 million restricted Class A shares, and a whopping 44.9 million restricted Class B shares.

The lock-up’s the real kicker. A decade-long commitment screams confidence, signaling WiMi sees MicroAlgo as a long-haul winner.

WiMi’s not new to MicroAlgo, as it held 63.32% and $23 million in convertible notes. The lock-up keeps MLGO’s float tight at 2 million shares, potentially fueling a squeeze, with 17% short interest still lurking.

Portage Biotech (NASDAQ:PRTG) unveiled a breakthrough at the 2025 European Lung Cancer Congress (ELCC) in Paris. New preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, showcased jaw-dropping results against mesothelioma, a notoriously tough cancer. Presented by Dr. Luciano Mutti of Gruppo Italiano Mesotelioma e Oncologia Ambientale, the findings revealed single-agent tumor suppression and a stunning >90% tumor growth halt when paired with an anti-PD1 antibody in a murine model. Tumor analysis lit up with CD3 and CD45 immune cells storming in, hinting at a revved-up immune attack.

Please click here to view ValueScope’s Core Gaming valuation report or additional 247marketnews.com Siyata disclosure at https://247marketnews.com/syta-siyata/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (LXRX, SYTA, DBVT, WIMI, MLGO, PRTG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.